<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32985910</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1-2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>143</EndPage><MedlinePgn>133-143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1822411</ELocationID><Abstract><AbstractText>To assess whether pre-diagnostic lipid levels are associated with Amyotrophic lateral sclerosis (ALS) risk. <i>Methods:</i> We conducted a matched case-control study nested in five large prospective US cohorts (the Nurses' Health Study, the Health Professionals Follow-up Study, the Cancer Prevention Study II Nutrition Cohort, the Multiethnic Cohort Study, and the Women's Health Initiative), and identified 275 individuals who developed ALS during follow-up and had provided blood samples before disease diagnosis. For each ALS case, we randomly selected two controls who were alive at the time of the case diagnosis and matched on cohort, birth year (&#xb1;1 year), sex, race/ethnicity, fasting status, and time of blood draw. We measured total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels in the plasma samples, and used conditional logistic regression to estimate associations between lipid levels and ALS risk. <i>Results:</i> Higher levels of HDL-C were associated with higher ALS risk in an analysis adjusted for the matching factors (risk ratio [RR] Q4 vs. Q1: 1.78, 95% confidence interval [CI]: 1.18-2.69, <i>p</i> trend: 0.007). The estimate remained similar in a multivariable analysis additionally adjusted for body mass index, physical activity, smoking, alcohol intake, plasma urate levels, and use of cholesterol-lowering drugs (RR Q4 vs. Q1: 1.71, 95% CI: 1.07-2.73, <i>p</i> trend: 0.02). Plasma levels of TC, LDL-C, and TG were not associated with ALS risk. <i>Conclusions:</i> Higher pre-diagnostic HDL-C levels, but not levels of other lipids, were associated with a higher risk of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bjornevik</LastName><ForeName>Kjetil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>&#xc9;ilis J</ForeName><Initials>&#xc9;J</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, College of Medicine, University College Cork, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortese</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtado</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolonel</LastName><ForeName>Laurence N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Marchand</LastName><ForeName>Loic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mccullough</LastName><ForeName>Marjorie L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Population Science, American Cancer Society, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarzschild</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadyab</LastName><ForeName>Aladdin H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Family Medicine and Public Health, School of Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>Joann E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascherio</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201600002C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201600018C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA167552</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201600003C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA186107</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201600004C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201600001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA049449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045893</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA164973</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">risk factors in epidemiology</Keyword></KeywordList><CoiStatement>Declaration of Interest Statement. Dr. Kjetil Bjornevik reports no disclosures. Dr. &#xc9;ilis J. O&#x2019;Reilly reports no disclosures. Dr. Marianna Cortese reports no disclosures. Dr. Jeremy D. Furtado reports no disclosures. Dr. Laurence N. Kolonel reports no disclosures. Dr. Loic Le Marchand reports no disclosures. Dr. Marjorie L. McCullough reports no disclosures. Dr. Sabrina Paganoni reports research grants from Amylyx Pharmaceuticals, Revalesio Corporation, the ALS Association, ALS Finding a Cure, the American Academy of Neurology, the Salah Foundation, the Spastic Paraplegia Foundation. Dr. Michael A. Schwarzschild reports no disclosures. Dr. Aladdin H. Shadyab reports being a consultant for Rancho BioSciences, LLC. Dr. JoAnn E. Manson reports no disclosures. Dr. Alberto Ascherio reports no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>28</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32985910</ArticleId><ArticleId IdType="mid">NIHMS1660210</ArticleId><ArticleId IdType="pmc">PMC8004541</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1822411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Seals RM, Gredal O, Mittleman MA, Hansen J, Weisskopf MG. Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:548&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178102</ArticleId><ArticleId IdType="pubmed">27436717</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wotton C, Talbot K, Goldacre MJ. Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. J Neurol Neurosurg Psychiatry 2012;83:395&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072701</ArticleId></ArticleIdList></Reference><Reference><Citation>Korner S, Kollewe K, Ilsemann J, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 2013;20:647&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, de Jong SW, Verwijs MC, et al. Family history of neurodegenerative and vascular diseases in ALS: a population-based study. Neurology 2011;77:1363&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940614</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser AE, Seelen M, Hulsbergen A, et al. Exploring the fitness hypothesis in ALS: a population-based case-control study of parental cause of death and lifespan. J Neurol Neurosurg Psychiatry 2017;88:550&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">28292782</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly EJ, Wang M, Adami HO, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:396&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6423444</ArticleId><ArticleId IdType="pubmed">29658324</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberg M, Nyberg J, Robertson J, et al. Risk factors in Swedish young men for amyotrophic lateral sclerosis in adulthood. J Neurol 2018;265:460&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834569</ArticleId><ArticleId IdType="pubmed">29285652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O, Meyer HE, Stigum H, Holmoy T. High BMI is associated with low ALS risk: A population-based study. Neurology 2019;93:e424&#x2013;e432.</Citation><ArticleIdList><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 2015;22:1436&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. JAMA Neurol 2015;72:905&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2032;Ovidio F, d&#x2032;Errico A, Carna P, Calvo A, Costa G, Chio A. The role of premorbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol 2018;25:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 2014;261:1949&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstrom H, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol 2017;81:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging 2018;67:202 e201&#x2013;202 e206.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019;85:470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet 2019;28:688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y, Bertoia ML, Lenart EB, et al. Origin, Methods, and Evolution of the Three Nurses&#x2019; Health Studies. Am J Public Health 2016;106:1573&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981810</ArticleId><ArticleId IdType="pubmed">27459450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991;338:464&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">1678444</ArticleId></ArticleIdList></Reference><Reference><Citation>Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490&#x2013;2501.</Citation><ArticleIdList><ArticleId IdType="pubmed">12015775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482109</ArticleId><ArticleId IdType="pubmed">10695593</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson GL, Manson J, Wallace R, et al. Implementation of the Women&#x2032;s Health Initiative study design. Ann Epidemiol 2003;13:S5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14575938</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 2004;160:26&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229114</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997&#x2013;2011. Neurol Clin Pract 2013;3:313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787117</ArticleId><ArticleId IdType="pubmed">24195020</ArticleId></ArticleIdList></Reference><Reference><Citation>Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol 2008;168:1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">18794220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929379</ArticleId><ArticleId IdType="pubmed">27122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffner SM, American Diabetes A. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27 Suppl 1:S68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">14693930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med 2012;172:1707&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">23147400</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S. &#x2018;Mendelian randomization&#x2019;: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado JD, Yamamoto R, Melchior JT, et al. Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. Arterioscler Thromb Vasc Biol 2018;38:2827&#x2013;2842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309805</ArticleId><ArticleId IdType="pubmed">30571168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks FM, Jensen MK. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2018;38:487&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823773</ArticleId><ArticleId IdType="pubmed">29371248</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerging Risk Factors C, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011;377:1085&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145074</ArticleId><ArticleId IdType="pubmed">21397319</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215&#x2013;2222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904878</ArticleId><ArticleId IdType="pubmed">20609967</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Is cardiovascular fitness a risk factor for ALS? J Neurol Neurosurg Psychiatry 2017;88:538.</Citation><ArticleIdList><ArticleId IdType="pubmed">28292783</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001;74:328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005;2:202&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 2018;89:1016&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Murthy SB, Wilson AM, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 2010;11:542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;383:2065&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannucci E, Stampfer MJ, Colditz GA, et al. A comparison of prospective and retrospective assessments of diet in the study of breast cancer. Am J Epidemiol 1993;137:502&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">8465802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Stickler DE, Royer JA, Hardin JW. Accuracy and usefulness of ICD-10 death certificate coding for the identification of patients with ALS: results from the South Carolina ALS Surveillance Pilot Project. Amyotroph Lateral Scler 2012;13:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">21929354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675622</ArticleId><ArticleId IdType="pubmed">25946516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>